Fortive (FTV) Q2 2025 earnings review
First Quarter as 'New Fortive': Revenue Reverses on Late-Quarter Shock, But Resilient Profits Signal a Grind Ahead
In its first quarter as a simplified company following the Ralliant spin-off, Fortive's results were a tale of two cities. Revenue growth reversed to a 0.7% core decline, missing expectations due to a sudden demand drop-off late in the quarter. Management cited a trifecta of headwinds hitting in June: tariff uncertainty deferring industrial orders, constrained government spending, and healthcare policy changes pausing hospital capex. Despite the top-line weakness, profitability proved remarkably resilient, with adjusted EPS growing 4% to $0.58, showcasing the benefit of the Fortive Business System and a higher-margin recurring revenue base. However, the cautious full-year guidance, which implies no significant recovery in the second half, suggests the macro challenges are expected to persist.
🐂 Bull Case
The spin-off of Ralliant is complete, leaving a more focused Fortive with ~50% recurring revenue. This simplified structure and durable revenue base should allow for more targeted strategies and capital allocation.
Despite the revenue decline, adjusted EBITDA margins were stable at 28.4%, and TTM free cash flow grew a solid 14% to $939 million. This demonstrates strong operational control and the ability to protect earnings in a tough environment.
Management characterized the revenue shortfall as resulting from delayed, not canceled, customer spending. Backlog at Fluke increased, and essential government and healthcare projects are still in the pipeline, suggesting a potential catch-up in future quarters.
🐻 Bear Case
After several quarters of positive, albeit slowing, growth, core revenue turned negative. The sharp drop-off in the final weeks of June signals poor near-term visibility and vulnerability to macro policy shifts.
The full-year outlook assumes H2 core growth will be similar to the weak H1 performance (less than 1%). This contradicts the idea that the Q2 issues were just a temporary blip and points to a more challenging environment ahead.
The company is battling on several fronts: intensifying tariff impacts ($40-55M gross headwind in H2), fiscal tightening in government channels, and policy uncertainty in healthcare. These external factors are largely outside of management's control.
⚖️ Verdict: 🔴
Bearish. The sharp, negative reversal in revenue growth across both core segments is a significant red flag that outweighs the resilient profitability. The cautious guidance, which implies a continuation of these weak trends, suggests management does not see a quick recovery. The bear case of persistent macro and policy headwinds appears more compelling than the bull case of a temporary deferral.
Key Themes
The 'June Swoon': A Sudden, Multi-Front Demand Shock
The quarter's results were derailed by an abrupt downturn in the final few weeks, resulting in a ~$30 million revenue shortfall. Management detailed three distinct issues: 1) Tariff uncertainty caused customers to defer spending on Fluke professional instruments, shifting orders to longer-lead time products and building backlog instead of revenue. 2) Constrained state and local government spending muted the typical June year-end 'use it or lose it' budget flush at Gordian. 3) Hospitals paused capital equipment purchases (ASP sterilization) while awaiting clarity on new healthcare reimbursement policies. This confluence of events highlights the company's sensitivity to policy uncertainty and creates concern around near-term visibility.
Core Growth Trend is Decelerating and Reversing
This quarter's negative core growth is not an isolated event but the culmination of a year-long slowdown. Core growth for continuing operations has steadily declined from 4.9% in Q1 2024 to 3.9% in Q2 2024, then 2.2% last quarter, before turning negative at -0.7% in Q2 2025. This persistent deceleration contradicts any narrative of underlying business momentum and signals that the operating environment is becoming progressively more difficult.
Tariff Headwinds Intensify
Tariffs have moved from a modeled risk to a direct cause of business disruption. Management now expects a gross impact of $40-$55 million in the second half of 2025 and directly cited tariff uncertainty as a reason for deferred customer spending at Fluke. While the company plans to fully mitigate the impact with countermeasures by Q4, it will create a 'modest gross margin and EPS headwind in Q3' and is clearly affecting customer behavior now.
Profitability and Cash Flow Remain Resilient
A key positive is the company's ability to protect the bottom line. Despite the revenue miss, adjusted EBITDA margin was nearly flat year-over-year at 28.4%. Adjusted EPS grew 4%, and trailing twelve-month free cash flow increased a strong 14% to $939 million. This performance, attributed to the Fortive Business System (FBS) and a favorable mix of recurring revenues, provides the foundation for the company's capital return strategy.
Innovation Engine Continues to Deliver
Fortive is executing on its strategy to drive organic growth through innovation. Management highlighted several recent launches, including Fluke's award-winning Multifunction Installation Tester, Gordian's new cloud-based capital planning module driving double-digit orders, and Provation's new AI Assistants designed to improve healthcare workflow productivity. These initiatives support the long-term growth story beyond near-term macro volatility.
Disciplined Capital Allocation Post-Spin
With the Ralliant spin-off complete and a $1.15 billion dividend received, Fortive is actively executing its new capital plan. The company used ~$725 million to pay down debt, bringing leverage to its 2.5x target, and plans to use the remainder for share repurchases. A clear focus on bolt-on M&A and buybacks, fueled by strong free cash flow, is a primary pillar of the value creation strategy.
Other KPIs
Both of Fortive's core segments saw growth reverse into negative territory. Intelligent Operating Solutions (IOS) slipped to -0.2% core growth, impacted by delayed industrial and government spending. Advanced Healthcare Solutions (AHS) saw a more pronounced drop to -1.9% core growth as hospitals paused equipment purchases. This synchronized downturn across the 'New Fortive' portfolio is a notable concern.
Up 14% YoY. Despite a quarterly decline in FCF to $180M (vs $198M YoY), the trailing twelve-month figure remains robust. This strong cash generation profile underpins the company's ability to invest in growth, pay a dividend, and execute its share repurchase program, providing a key layer of support for shareholder returns.
Management noted that adjusted gross margins were stable year-over-year. Positive drivers like FBS-driven pricing actions, growth in high-margin recurring revenues, and supply chain savings were able to offset the negative pressure from tariff-related costs. This demonstrates effective cost management in a difficult environment.
Guidance
Stable. The full-year guidance implies a heavily back-loaded year. H1 EPS was $1.13, meaning the H2 guidance midpoint is $1.42, a 26% increase over H1. Management expects Q3 EPS to be slightly below Q2's $0.58, implying a very strong Q4 is needed to hit the annual target. This ramp is predicated on tariff mitigation, lower interest costs, and a significantly lower Q4 tax rate, rather than a major revenue recovery.
Decelerating. H1 core growth was approximately 0.75%. Guidance for a similar performance in H2 implies a continuation of the weak demand environment seen in Q2. This represents a significant deceleration from the growth rates seen in 2024 and indicates management does not anticipate a near-term rebound.
Management expects Q3 reported revenue to be similar to Q2's $1.02 billion. Adjusted EBITDA is expected to be seasonally lower, and EPS will be further pressured by tariff headwinds and a higher tax rate (high teens) before countermeasures and tax benefits boost Q4.